Expression and its functional role of Beta3-adrenoceptors in the human prostate

• Project/Area Number: 23592365
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: OTSUKA Atsushi 浜松医科大学, 医学部, 助教 (90362201)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000); Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2012: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000); Fiscal Year 2011: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
• Keywords: 前立腺 / β-アドレナリン受容体 / ヒト / β3-アドレナリン受容体 / 平滑筋 / β‐アドレナリン受容体 / β3‐アドレナリン受容体

Research Abstract

Expression of beta1-, beta2- and beta3-AR mRNA in the human prostate was confirmed by RT-PCR. On immunohistochemistry, positive staining for beta1-, beta2- and beta3-AR was identified not only in prostatic smooth muscles, but also glandular epithelium. In pharmacological study in vitro, a beta3-AR agonist concentration-dependently decreased KCL- or EFS-induced contraction of the human normal prostatic strips. In conclusion, beta3-AR agonists may have clinical benefit for lower urinary tract symptom due to either benign prostatic hyperplasia or neurogenic bladder.